March 11, 2020 / 12:30 PM / a month ago

BRIEF-Scynexis Expects Top-Line Data For Phase 3 Candle Study Of Oral Ibrexafungerp In H2 2021

March 11 (Reuters) - SCYNEXIS Inc:

* SCYNEXIS REPORTS FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE

* SCYNEXIS - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TOTALED $48.4 MILLION AS OF DEC 31, 2019

* SCYNEXIS INC - ENROLLMENT IS ONGOING IN PHASE 3 CANDLE STUDY OF ORAL IBREXAFUNGERP FOR PREVENTION OF RECURRENT VAGINAL YEAST INFECTIONS

* SCYNEXIS INC - ANTICIPATE TOP-LINE DATA FOR PHASE 3 CANDLE STUDY OF ORAL IBREXAFUNGERP AND SUPPLEMENTAL NDA SUBMISSION IN SECOND HALF OF 2021 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below